Ariad interim Phase II advanced sarcoma data

ARIA said that in a Phase II trial of AP23573 to treat advanced sarcoma, 19 of 52 evaluable patients had clinical-benefit responses, or sustained anti-tumor activity defined by RECIST, the primary end...